Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy

Cancer Biology & Therapy
Mayra Ramos-SuzarteTania Crombet Ramos

Abstract

Over-expression of epidermal growth factor receptor in esophageal cancer is associated with poor prognosis. The present study was conducted to evaluate safety and preliminary efficacy of nimotuzumab, a humanized anti-EGFR antibody in combination with radiation and chemotherapy in advanced esophageal tumours. A Phase II clinical trial was conducted, where patients received cisplatin, 5-fluorouracil, and radiotherapy, either alone or combined with six weekly infusions of nimotuzumab at the dose of 200 mg. Safety was the primary endpoint. The antitumoral objective response rate was the secondary endpoint. Epidermal growth factor receptor expression, KRAS mutation status and anti-idiotypic response were also evaluated. Sixty-three patients were included in the study. Thirty patients were entered into the control group, and thirty-three patients received the treatment with nimotuzumab. The antibody was very well tolerated. Objective response rate was 47.8 % (nimotuzumab group) and 15.4 % (control group). Disease control rate was 60.9 % (nimotuzumab group) and 26.9 % (control group). Response and disease control rate were higher in patients with EGFR overexpressing tumors. Nimotuzumab plus chemoradiotherapy was safe and provided stat...Continue Reading

References

Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B A BatesJ E Tepper
Mar 1, 1997·Immunotechnology : an International Journal of Immunological Engineering·C MateoR Pérez
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tania CrombetAgustín Lage
Jun 1, 2005·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·G Chong, D Cunningham
Jul 18, 2006·Current Topics in Medicinal Chemistry·David B Solit, Neal Rosen
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bernard M TijinkGuus A M S van Dongen
Jul 11, 2007·The Cancer Journal·Geoffrey Y Ku, David H Ilson
Jul 11, 2007·The Cancer Journal·Christopher G WillettJohanna C Bendell
Oct 23, 2008·JAMA : the Journal of the American Medical Association·Thijs J GiezenAntoine C G Egberts
Jan 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio JimenoS Gail Eckhardt
Apr 28, 2009·Current Treatment Options in Oncology·Wei LiuWeijing Sun
Jul 8, 2009·BMC Cancer·Magbubah EssackVladimir B Bajic
Aug 6, 2009·Journal of Gastroenterology and Hepatology·Stephan KerstingHans D Saeger
Nov 26, 2009·Carcinogenesis·Michael J ThunElizabeth M Ward
Jan 5, 2010·MAbs·Mahendra P DeonarainAgamemnon A Epenetos
Feb 13, 2010·Expert Opinion on Therapeutic Targets·Simon EkmanJohan Lennartsson
Mar 27, 2010·The Annals of Thoracic Surgery·Sjoerd M LagardeJ Jan B van Lanschot

❮ Previous
Next ❯

Citations

May 18, 2013·Current Opinion in Oncology·Patrick M Boland, Barbara Burtness
May 3, 2014·Cancer Biotherapy & Radiopharmaceuticals·Ricardo CabanasTania Crombet Ramos
Jul 17, 2013·Expert Opinion on Therapeutic Targets·Liu HongLubi Brain
Jun 21, 2014·Expert Opinion on Investigational Drugs·Sing Yu Moorcraft, Ian Chau
Feb 20, 2016·Expert Review of Gastroenterology & Hepatology·Lei ZhangDaiming Fan
Oct 16, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J JiaX Zhang
Mar 14, 2013·Oncoimmunology·Erika VacchelliLorenzo Galluzzi
Mar 8, 2014·Oncoimmunology·Erika VacchelliLorenzo Galluzzi
Sep 29, 2015·Biomedizinische Technik. Biomedical Engineering·Stefan Odenbach
Jan 20, 2017·Oncology Letters·Xiao-Ying Zhang, Pei-Ying Zhang
Jun 17, 2020·Frontiers in Oncology·Tania Crombet RamosNormando E Iznaga Escobar
Sep 19, 2018·Journal of Obstetrics and Gynaecology of India·Shyamji Rawat
Dec 23, 2020·Journal of the National Cancer Institute·Salma K JabbourMansoor M Ahmed

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.